874PTreatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. (23rd October 2018) - McDermott, D F; Rini, B I; Motzer, R J; Tannir, N M; Escudier, B; Kollmannsberger, C K; Hammers, H J; Porta, C; George, S; Donskov, F; Gurney, H P; Grimm, M-O; et al.